Pfizer Inc. Stock
Pfizer Inc. Stock
Pfizer Inc. gained 1.580% today.
We see a rather positive sentiment for Pfizer Inc. with 13 Buy predictions and 2 Sell predictions.
As a result the target price of €55.00 shows a slightly positive potential of 14.823% compared to the current price of €47.90 for Pfizer Inc..
For the coming years our community has positive and negative things to say abot the Pfizer Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Conscious of the environment" there were negative voices in the community.
Pros and Cons of Pfizer Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 1.580% | 0.188% | -8.378% | 59.907% | -5.986% | 42.296% | 71.781% |
| Eli Lilly Corp. | 0.760% | -1.255% | -13.588% | 23.805% | -13.869% | 110.589% | 202.134% |
| Merck & Co. Inc. | 2.900% | 1.204% | 6.907% | 13.292% | 6.200% | 12.920% | 25.486% |
| AbbVie Inc. | 2.090% | 3.689% | 2.781% | 43.675% | 2.470% | 72.825% | 117.938% |
Comments
Other discussions about Pfizer Inc. Stock
Trading Pfizer Inc.
Trading Pfizer Inc.
News
Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment
Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License